Update: Availability of Streptomycin
and Para-Aminosalicylic Acid -- United States
Since April 1992, streptomycin (SM) and para-aminosalicylic
acid (PAS) (antimicrobial agents used in the treatment of
tuberculosis (TB)) have been available through CDC under an
investigational new drug agreement for the treatment of patients
with multidrug-resistant TB. SM will now be made available for use
in the drug-treatment regimen of any patient with active TB. This
announcement updates and supersedes the previous notice (1) on
availability of SM. Eligibility criteria for PAS remain unchanged.
Clinicians interested in obtaining SM or PAS for their patients
should provide an abbreviated medical history and, for SM, a recent
creatinine serum level measurement.
These drugs are expected to become commercially available in
the United States later this year. Until then, requests should be
directed to CDC's Clinical Research Branch, Division of
Tuberculosis Elimination, National Center for Prevention Services;
telephone (404) 639-2530.
Reference
CDC. Availability of streptomycin and para-aminosalicylic
acid -- United States. MMWR 1992;41:243
Disclaimer
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
